Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $197.50 short call and a strike $202.50 long call offers a potential 13.9% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $197.50 by expiration. The full premium credit of $0.61 would be kept by the premium seller. The risk of $4.39 would be incurred if the stock rose above the $202.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 43.01 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
Thu, 03 Oct 2019 21:45:09 +0000
In the latest trading session, Amgen (AMGN) closed at $192.62, marking a +1.8% move from the previous day.
Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar
Thu, 03 Oct 2019 19:49:50 +0000
Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value protein-based therapeutics and vaccines. The most advanced product candidate in Pfenex' pipeline, PF708, is inching closer to commercialization.
Merck's Pediatric Filings for Dificid Get FDA's Priority Review
Thu, 03 Oct 2019 15:22:03 +0000
The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
Amgen, Merck and Others Highlighted Cancer-Drug Developments in Barcelona
Thu, 03 Oct 2019 11:00:00 +0000
Companies including Amgen, Merck & Co., and Incyte offered positive news on a range of therapies at a major cancer conference sponsored by the European Society for Medical Oncology.
Seeing the Baseline
Wed, 02 Oct 2019 15:04:56 +0000
As contrarian value investors, we not only believe reversion is an eventuality, but that money can be made when the majority believe it to be dead Continue reading…
Also on Market Tamer…
Follow Us on Facebook